The media reports that colchicine, a very old drug, has now been discovered to reduce the risk of recurrent heart disease and has a new FDA indication. Of course, the “discovery” has taken 10 years, ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

The benefits of low-dose colchicine (Colcrys) are consistent if started months or years after acute coronary syndrome (ACS) in patients with stable coronary artery disease, a new LoDoCo2 subanalysis ...

An anti-inflammatory drug that has been around for over 2,000 years might help delay a very modern problem: hip and knee replacements. That's the suggestion of a new study finding that older adults ...

Please provide your email address to receive an email when new articles are posted on . In a meta-analysis of seven trials, colchicine was associated with reduced risk for MACE in patients with CAD ...

AMSTERDAM, the Netherlands—The use of colchicine just before major thoracic surgery and for 10 days afterwards does not lower the risk of clinically significant atrial fibrillation (AF) or myocardial ...

Colchicine is one of the oldest medicines with potent anti-inflammatory functions, widely used to treat rheumatic diseases such as gout, calcium pyrophosphate deposition disease (CPDD), and familial ...

Colchicine is a generic prescription medication used to prevent gout flares and treat familial Mediterranean fever (FMF) in adults and certain children. Like most drugs, colchicine can cause side ...

Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, ...

Please provide your email address to receive an email when new articles are posted on . In patients with chronic coronary disease, the beneficial effects of colchicine were consistent regardless of ...